Dose-response effect of prebiotic ingestion (β-glucans isolated from Saccharomyces cerevisiae) in diabetic rats with periodontal disease

dc.creatorAzzi, Diana Vilela
dc.creatorPereira, Andressa Naira de Jesus
dc.creatorSilva, Viviam de Oliveira
dc.creatorFoureaux, Renata de Carvalho
dc.creatorLima, Andressa Ribeiro Veiga
dc.creatorBarducci, Robson Sfaciotti
dc.creatorAlbuquerque, Adriana Silva
dc.creatorReis, Gabriel Lasmar
dc.creatorOliveira, Raphael Ricon de
dc.creatorAndrade, Eric Francelino
dc.creatorZangeronimo, Márcio Gilberto
dc.creatorChalfun Júnior, Antonio
dc.creatorPereira, Luciano José
dc.date.accessioned2022-01-24T20:28:50Z
dc.date.accessioned2023-06-27T19:57:04Z
dc.date.available2022-01-24T20:28:50Z
dc.date.available2023-06-27T19:57:04Z
dc.date.issued2021-10
dc.description.abstractBackground: Periodontal disease is one of the most frequent comorbidities in diabetic patients and can contribute to poor blood glucose control. Objective: To evaluate the efects of ingesting diferent doses of beta-glucans (BG) isolated from Saccharomyces cer‑ evisiae on alveolar bone loss (ABL) and infammatory/metabolic parameters in normal and diabetic rats with ligatureinduced periodontal disease (PD). Design: Sixty male rats were assigned into two groups: non-diabetic or diabetic (i.p. 70 mg/kg streptozotocin) with PD. Then, groups were subdivided into fve subgroups according BG doses: 0 mg/Kg; 10 mg/Kg; 20 mg/Kg; 40 mg/Kg or 80 mg/Kg. Animals received BG for 28 days and ligatures were placed on lower frst molars during the last 14 days. Results: ABL of diabetic and non-diabetic animals receiving BG 40 mg/kg (1.33 ± 0.03 mm and 0.77 ± 0.07 mm, respectively) and 80 mg/kg (1.26 ± 0.07 mm and 0.78 ± 0.05 mm, respectively) doses was lower (p < 0.05) in com‑ parison to respective controls (1.59 ± 0.11 mm and 0.90 mm ±0.08). COX-2 (Control: 1.66 ± 0.12; 40 mg/kg: 1.13 ± 0.07; 80 mg/kg: 0.92 ± 0.18) and RANKL expressions (Control: 1.74 ± 0.34; 40 mg/kg: 1.03 ± 0.29 ;80 mg/kg: 0.75 ± 0.21), together with the RANKL/OPG ratio (Control: 1.17 ± 0.08; 40 mg/kg: 0.67 ± 0.09; 80 mg/kg: 0.63 ± 0.28) were attenuated above the same dose (p < 0.05). BG did not infuence (p > 0.05) metabolic parameters in non-diabetic rats. In diabetic animals, doses above 40 mg/kg reduced IL-1β (Control: 387 ± 66; 40 mg/kg: 309 ± 27; 80 mg/kg: 300 ± 14) and TNF-α (Control: 229 ± 19; 40 mg/kg: 128 ± 53; 80 mg/kg: 71 ± 25), blood glucose levels (Control: 402 ± 49; 40 mg/kg: 334 ± 32; 80 mg/kg: 287 ± 56), total cholesterol (Control: 124 ± 8; 40 mg/kg: 120 ± 10; 80 mg/kg: 108 ± 9), LDL-c + VLDL-c (Control: 106 ± 8; 40 mg/kg: 103 ± 10; 80 mg/kg: 87 ± 10) and triacylglycerols (Control: 508 ± 90; 40 mg/kg: 301 ± 40; 80 mg/kg: 208 ± 61), whereas increased HDL-c (Control: 18 ± 0.5; 40 mg/kg: 19 ± 1; 80 mg/kg: 21 ± 1) (p < 0.05). Optimal dose needed to reduce ABL was higher in diabetic animals with PD.pt_BR
dc.identifier.citationAZZI, D. V. et al. Dose-response effect of prebiotic ingestion (β-glucans isolated from Saccharomyces cerevisiae) in diabetic rats with periodontal disease. Diabetology & Metabolic Syndrome, [S. I.], v. 13, 2021. DOI: https://doi.org/10.1186/s13098-021-00729-1.pt_BR
dc.identifier.urihttps://repositorio.ufla.br//handle/1/57802
dc.languageen_USpt_BR
dc.publisherSpringer Naturept_BR
dc.rightsAttribution 4.0 International*
dc.rightsAttribution 4.0 International
dc.rightsacesso abertopt_BR
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceDiabetology & Metabolic Syndromept_BR
dc.subjectPeriodontitispt_BR
dc.subjectDiabetes mellituspt_BR
dc.subjectBone losspt_BR
dc.subjectInflammatory statuspt_BR
dc.subjectβ-glucanspt_BR
dc.subjectPeriodontitept_BR
dc.subjectPerda ósseapt_BR
dc.subjectStatus inflamatóriopt_BR
dc.subjectβ-glucanospt_BR
dc.subjectPrebióticospt_BR
dc.titleDose-response effect of prebiotic ingestion (β-glucans isolated from Saccharomyces cerevisiae) in diabetic rats with periodontal diseasept_BR
dc.typeArtigopt_BR

Arquivos